

# Kevin Kalinsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3153520/publications.pdf>

Version: 2024-02-01

107  
papers

2,563  
citations

218677

26  
h-index

214800

47  
g-index

107  
all docs

107  
docs citations

107  
times ranked

4732  
citing authors

#	ARTICLE	IF	CITATIONS
1	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5049-5059.	7.0	338
2	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	7.1	260
3	AKT in cancer: new molecular insights and advances in drug development. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 943-956.	2.4	209
4	Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1148-1156.	1.2	146
5	A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). <i>Cancer</i> , 2017, 123, 2688-2697.	4.1	103
6	Inhibition of the autocrine IL-6/JAK2-STAT3-calprotectin axis as targeted therapy for HR <sup>+</sup> /HER2 <sup>+</sup> breast cancers. <i>Genes and Development</i> , 2015, 29, 1631-1648.	5.9	94
7	Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. <i>Annals of Oncology</i> , 2020, 31, 1709-1718.	1.2	86
8	Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 150-157.	1.3	66
9	¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2015, 115, 709-723.e3.	0.8	51
10	Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 555-564.	2.5	50
11	PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 635-643.	2.5	49
12	Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.	7.1	49
13	Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. <i>Clinical and Translational Oncology</i> , 2015, 17, 539-546.	2.4	45
14	Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 239-242.	2.5	43
15	Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer. <i>Radiology</i> , 2018, 287, 778-786.	7.3	39
16	Cracking Open Window of Opportunity Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 2573-2575.	1.6	36
17	Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. <i>JCO Oncology Practice</i> , 2021, 17, e1215-e1224.	2.9	36
18	Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 277-288.	2.5	35

#	ARTICLE	IF	CITATIONS
19	Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast Journal, 2015, 21, 377-386.	1.0	34
20	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. Nature Cancer, 2021, 2, 658-671.	13.2	34
21	Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The <i>¡Cocinar Para Su Salud!</i> Randomized Controlled Trial. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1491-1502.	2.5	33
22	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment, 2018, 170, 547-557.	2.5	32
23	Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Research and Treatment, 2018, 171, 11-20.	2.5	32
24	Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Drugs of Today, 2019, 55, 575.	1.1	30
25	Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS ONE, 2015, 10, e0145816.	2.5	28
26	A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).. Journal of Clinical Oncology, 2020, 38, 1015-1015.	1.6	28
27	Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. SpringerPlus, 2015, 4, 386.	1.2	27
28	¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. Journal of the Academy of Nutrition and Dietetics, 2015, 115, S42-S56.e3.	0.8	27
29	An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Medicine, 2016, 5, 2641-2648.	2.8	25
30	Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features. Clinical Breast Cancer, 2018, 18, 229-233.	2.4	25
31	Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Annals of Oncology, 2022, 33, 702-712.	1.2	24
32	Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S40479.	1.3	22
33	Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, 80-86.	2.4	22
34	Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Clinical and Translational Oncology, 2018, 20, 1474-1483.	2.4	20
35	Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clinical Breast Cancer, 2021, 21, 383-390.	2.4	18
36	Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research, 2020, 80, CT011-CT011.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 533-540.	2.5	15
38	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
39	A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e251-e260.	2.4	15
40	Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 968.	2.8	15
41	Phase I/II trial of ruxitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 177-185.	2.5	15
42	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 127-139.	2.5	15
43	Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 439-444.	1.3	14
44	Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. <i>Future Oncology</i> , 2019, 15, 1641-1653.	2.4	14
45	Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1004-1004.	1.6	14
46	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). <i>Clinical Breast Cancer</i> , 2020, 20, 183-193.	2.4	13
47	A phase Ib study of abemaciclib with therapies for metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 522-522.	1.6	13
48	Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. <i>International Journal of Food Science, Nutrition and Dietetics</i> , 2015, 2015, 1-9.	0.0	13
49	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. <i>Cancer</i> , 2020, 126, 1541-1549.	4.1	12
50	Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 427-432.	2.5	12
51	Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations and Prognosis. <i>Clinical Breast Cancer</i> , 2018, 18, 114-120.	2.4	11
52	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.9	11
53	Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. <i>Clinical and Translational Oncology</i> , 2017, 19, 180-188.	2.4	9
54	Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. <i>Biomedical Optics Express</i> , 2019, 10, 4305.	2.9	9

#	ARTICLE	IF	CITATIONS
55	Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2021, 39, 1005-1005.	1.6	8
56	Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, e150-e153.	2.4	7
57	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideâ„¢ Assay. Clinical Breast Cancer, 2022, 22, e457-e462.	2.4	6
58	Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in Oncology, 2021, 11, 810023.	2.8	6
59	Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy. Clinical Breast Cancer, 2020, 20, e327-e333.	2.4	5
60	On the Road to Precision: Understanding the Biology Driving Genomic Assays. Journal of Clinical Oncology, 2021, 39, 100-102.	1.6	5
61	Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes. Clinical Cancer Research, 2021, 27, 1949-1957.	7.0	5
62	Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).. Journal of Clinical Oncology, 2017, 35, 327-327.	1.6	5
63	Immunocytochemistry staining for ER and PR in circulating tumor cells as compared to primary tumor or metastatic biopsy.. Journal of Clinical Oncology, 2012, 30, 584-584.	1.6	5
64	Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy. Clinical and Translational Oncology, 2018, 20, 1280-1288.	2.4	4
65	Dynamic Vascular Optical Tomographic Imaging for Peripheral Artery Disease and Breast Cancer. , 2019, , 353-400.		4
66	Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).. Journal of Clinical Oncology, 2016, 34, 8559-8559.	1.6	4
67	A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS1112-TPS1112.	1.6	4
68	Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. Breast Cancer Research and Treatment, 2022, 192, 509-516.	2.5	4
69	Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA</i>-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).. Journal of Clinical Oncology, 2022, 40, 1052-1052.	1.6	4
70	Lymph node involvement: Positive about the role of the recurrence score in estrogenâ€ driven breast cancer?. Cancer, 2019, 125, 177-180.	4.1	3
71	Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?. Clinical Cancer Research, 2020, 26, 1781-1783.	7.0	3
72	When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e79-e89.	3.8	3

#	ARTICLE	IF	CITATIONS
73	Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2 <sup>+</sup> negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 1-13.	2.5	3
74	Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2613-2613.	1.6	3
75	A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9501-9501.	1.6	3
76	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA509-LBA509.	1.6	3
77	Bevacizumab in breast cancer: a targeted therapy still in search of a target population. <i>Seminars in Oncology</i> , 2017, 44, 286-287.	2.2	2
78	Obesity <sup>™</sup> s impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 285-285.	2.5	2
79	Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 297-304.	2.5	2
80	Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. <i>Breast Cancer Research</i> , 2021, 23, 16.	5.0	2
81	A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8522-8522.	1.6	2
82	Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	3.0	1
83	A phase I/II study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC). <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021, 18, .	0.0	1
84	Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10516-10516.	1.6	1
85	Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1058-1058.	1.6	1
86	A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1103-TPS1103.	1.6	1
87	Phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 598-598.	1.6	1
88	Individualizing Adjuvant Therapy in Women With Hormone Receptor <sup>+</sup> Positive, Human Epidermal Growth Factor Receptor 2 <sup>+</sup> Negative Node-Positive Breast Cancer. <i>JCO Oncology Practice</i> , 2022, , OP2100780.	2.9	1
89	Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. <i>Cancer Investigation</i> , 2021, 39, 466-472.	1.3	0
90	Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
91	Integration of germline multigene panel testing into breast and gynecologic oncology clinics.. Journal of Clinical Oncology, 2021, 39, 164-164.	1.6	0
92	Ethnic differences in tumor proliferation in women with early-stage breast cancer.. Journal of Clinical Oncology, 2013, 31, 560-560.	1.6	0
93	Correlation between risk benefit index and uptake of breast cancer chemoprevention.. Journal of Clinical Oncology, 2014, 32, 1568-1568.	1.6	0
94	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS666-TPS666.	1.6	0
95	Identifying predictors of taxane-induced peripheral neuropathy using shotgun proteomics technology.. Journal of Clinical Oncology, 2015, 33, 9607-9607.	1.6	0
96	Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy.. Journal of Clinical Oncology, 2015, 33, e20738-e20738.	1.6	0
97	Lymphovascular invasion and survival in breast cancer after neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2016, 34, 1025-1025.	1.6	0
98	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology, 2016, 34, LBA509-LBA509.	1.6	0
99	Comparison of physicians, nurses' and patients' assessment of overall symptom burden.. Journal of Clinical Oncology, 2016, 34, e18123-e18123.	1.6	0
100	Pleomorphic invasive lobular breast carcinoma: Prognosis and characteristics compared with classical invasive lobular breast carcinoma.. Journal of Clinical Oncology, 2016, 34, e13094-e13094.	1.6	0
101	Differences in global toxicity burden among patients and care providers during initial chemotherapy for breast cancer.. Journal of Clinical Oncology, 2017, 35, e21649-e21649.	1.6	0
102	Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2017, 35, e12117-e12117.	1.6	0
103	Characterization of the tumor immune microenvironment (TIM) with multiplex immunohistochemistry (mIHC) in patients with breast cancer following treatment with MK-2206.. Journal of Clinical Oncology, 2017, 35, e12109-e12109.	1.6	0
104	Obesity and survival in the neoadjuvant breast cancer setting: Role of tumor subtype and race.. Journal of Clinical Oncology, 2017, 35, e12136-e12136.	1.6	0
105	Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).. Journal of Clinical Oncology, 2018, 36, 12057-12057.	1.6	0
106	The COVID-19 pandemic impact on breast cancer care delivery at an academic center in New York City.. Journal of Clinical Oncology, 2020, 38, 88-88.	1.6	0
107	Phase Ib/II study of BCL-2 inhibitor lisaftoclox (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER <sup>+</sup> ) breast cancer or advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS1122-TPS1122.	1.6	0